Revenue - Revenue Recognition (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Percentage of net sales	100.00%	100.00%	100.00%
Revenue Benchmark | Customer Concentration Risk | Biologics
Disaggregation of Revenue [Line Items]
Percentage of net sales	41.00%	41.00%	31.00%
Revenue Benchmark | Customer Concentration Risk | Generics
Disaggregation of Revenue [Line Items]
Percentage of net sales	18.00%	17.00%	20.00%
Revenue Benchmark | Customer Concentration Risk | Pharma
Disaggregation of Revenue [Line Items]
Percentage of net sales	24.00%	24.00%	26.00%
Revenue Benchmark | Customer Concentration Risk | Contract-Manufactured Products
Disaggregation of Revenue [Line Items]
Percentage of net sales	17.00%	18.00%	23.00%
Revenue Benchmark | Product Concentration Risk | High-Value Product Components
Disaggregation of Revenue [Line Items]
Percentage of net sales	55.00%	54.00%	46.00%
Revenue Benchmark | Product Concentration Risk | High-Value Product Delivery Devices
Disaggregation of Revenue [Line Items]
Percentage of net sales	5.00%	5.00%	5.00%
Revenue Benchmark | Product Concentration Risk | Standard Packaging
Disaggregation of Revenue [Line Items]
Percentage of net sales	23.00%	23.00%	26.00%
Revenue Benchmark | Product Concentration Risk | Contract-Manufactured Products
Disaggregation of Revenue [Line Items]
Percentage of net sales	17.00%	18.00%	23.00%
Revenue Benchmark | Geographic Concentration Risk | Americas
Disaggregation of Revenue [Line Items]
Percentage of net sales	48.00%	45.00%	48.00%
Revenue Benchmark | Geographic Concentration Risk | Europe, Middle East, Africa
Disaggregation of Revenue [Line Items]
Percentage of net sales	43.00%	45.00%	43.00%
Revenue Benchmark | Geographic Concentration Risk | Asia Pacific
Disaggregation of Revenue [Line Items]
Percentage of net sales	9.00%	10.00%	9.00%